New Approaches To Neuroblastoma Therapy Consortium

This early-phase study tested an oral drug called lorlatinib in 65 children and young adults with ALK-driven neuroblastoma that had come back or not responded to standard treatment. The goal was to find the safest dose and see how the drug works alone or with chemotherapy. The dr…

This early-phase study tested an intravenous form of the drug fenretinide in 17 children whose neuroblastoma had returned or resisted standard treatments. The main goals were to find the safest dose and understand side effects. Researchers also looked for signs that the drug migh…

This early-phase study tested a new approach for children with neuroblastoma that did not respond to standard treatments. It used two doses of a radioactive drug (I-MIBG) to target cancer cells, followed by a stem cell transplant to restore healthy blood cells. The goal was to fi…

This early-phase study tested a new treatment for children with high-risk neuroblastoma that did not respond to standard therapy or came back. The approach combines a radioactive drug (131I-MIBG) that targets tumor cells with two chemotherapy drugs (irinotecan and vincristine). T…

This study tested a treatment for children with a high-risk nerve cancer called neuroblastoma that had come back or not responded to standard therapy. It combined a radioactive drug (MIBG) that targets cancer cells with strong chemotherapy and a stem cell transplant to help the b…

This early-phase study tested an oral powder form of the drug fenretinide in 80 children whose neuroblastoma had returned or resisted standard treatment. The main goals were to find the safest dose and understand side effects. Researchers also looked at how the drug behaves in th…

This early-stage trial tested a combination of two chemotherapy drugs (irinotecan and temozolomide) plus an antibiotic (cefixime) in 30 children whose high-risk neuroblastoma had come back or not responded to treatment. The main goal was to find the safest dose of oral irinotecan…